Apatinib/Etoposide Promising in Platinum-Resistant Ovarian Cancer


Apatinib combined with etoposide offers promising efficacy in patients with platinum-resistant ovarian cancer.

A phase II trial found that apatinib combined with etoposide offers promising efficacy in patients with platinum-resistant ovarian cancer. The regimen could offer advantages due to its home-based administration that does not require hospital admission.

“Some preclinical studies have shown that the combination of oral topotecan and the angiogenesis inhibitor pazopanib was effective, and toxicity was tolerable in patients with solid tumors, including ovarian cancer,” wrote study authors led by Chun-Yan Lan, MD, of Sun Yat-sen University Cancer Center in Guangzhou, China. Apatinib is a small-molecule tyrosine kinase inhibitor that selectively inhibits VEGFR2, and has shown promise in earlier small studies of ovarian cancer.

The new AEROC trial was a single-arm phase II study, including 35 patients with platinum-resistant or platinum-refractory ovarian cancer, conducted at a single center. Patients received apatinib 500 mg once daily along with oral etoposide at a dose of 50 mg on days 1–14 of a 21-day cycle. Patients had a median age of 55 years, and most (63%) had received 3 to 6 prior lines of chemotherapy. The results of the trial were published in Lancet Oncology.

A total of 19 of 35 patients in the intention-to-treat population achieved an objective response to the treatment (54%); in 31 patients included in a per-protocol analysis, the objective response rate was 61%. Disease control was achieved in 30 patients, for a rate of 86% in the intention-to-treat population; the disease control rate was 97% in the per-protocol analysis. The median duration of response was 7.4 months, and the median progression-free survival in the study was 8.1 months.

Every patient in the study had at least one adverse event of any grade, regardless of cause. Four patients (12% of those with safety data) discontinued the study because of adverse events; these included neutropenia, hypertension, thrombocytopenia, and hand-foot syndrome. The most common grade 3/4 adverse events included neutropenia (50%), fatigue (32%), anemia (29%), and mucositis (24%). There were no fatal adverse events reported in the study; two patients had serious events and were admitted to the hospital.

The authors noted the study’s limitations, including its single-arm design, which could introduce the possibility for selection bias. Still, they concluded that “the combination of therapy of apatinib with oral etoposide shows promising efficacy and manageable toxicities in patients with platinum-resistant or platinum-refractory recurrent ovarian cancer, and further study in phase III trials is warranted.”

Recent Videos
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.
Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.
Brian Slomovitz, MD, MS, FACOG, notes that sometimes there is a need to substitute cisplatin for carboplatin, and vice versa, to best manage gynecologic cancers during the chemotherapy shortage.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Trastuzumab deruxtecan appears to elicit ‘impressive’ responses among patients with HER2-positive gynecologic cancers regardless of immunohistochemistry in the phase 2 DESTINY-PanTumor02 trial.
Related Content